title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
abstract: Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
authors.affiliation: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
authors.forename: J K
authors.initials: JK
authors.lastname: Hicks
authors.affiliation: University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Bishop
authors.affiliation: Department of Genetics, Stanford University, Stanford, California, USA.
authors.forename: K
authors.initials: K
authors.lastname: Sangkuhl
authors.affiliation: Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
authors.forename: D J
authors.initials: DJ
authors.lastname: Müller
authors.affiliation: Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Ji
authors.affiliation: Veterans Affairs San Diego Healthcare System, Mental Health Care Line, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Department of Psychiatry, San Diego, California, USA.
authors.forename: S G
authors.initials: SG
authors.lastname: Leckband
authors.affiliation: Division of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Leeder
authors.affiliation: Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Graham
authors.affiliation: Veterans Affairs Palo Alto Health Care System, San Jose Division, San Jose, California, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Chiulli
authors.affiliation: CICAB Clinical Research Center, Extremadura University Hospital and Medical School, Badajoz, Spain.
authors.forename: A
authors.initials: A
authors.lastname: LLerena
authors.affiliation: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
authors.forename: T C
authors.initials: TC
authors.lastname: Skaar
authors.affiliation: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Scott
authors.affiliation: Federal Institute of Drugs and Medical Devices, Bonn, Germany.
authors.forename: J C
authors.initials: JC
authors.lastname: Stingl
authors.affiliation: Department of Genetics, Stanford University, Stanford, California, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Caudle
authors.affiliation: Division of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
authors.forename: A
authors.initials: A
authors.lastname: Gaedigk
mesh_terms: D001711:Biotransformation; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics* / Q000378:metabolism; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D054796:Drug Dosage Calculations; D005838:Genotype; D006801:Humans; D061214:Patient Safety; D010597:Pharmacogenetics / Q000592:standards*; D010641:Phenotype; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D017367:Selective Serotonin Reuptake Inhibitors; C045793:CYP2C19 protein, human